Skip to content
Screener

Savara SVRA Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

XER
Xeris Biopharma Holdings, Inc.XERS
-$31.09M-1,513%
Upstream Bio, Inc. logo
Upstream Bio, Inc.UPB
-$39.93M+0.4%
PVL
Palvella TherapeuticsPVLA
-$15.76M-92.3%
TRV
Trevi Therapeutics, Inc.TRVI
-$13.53M-31.0%
Insmed logo
InsmedINSM
-$16.62M+94.8%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$78.24M+1,297%

Other financials

Income statement

See full
Revenue-
Operating income-$41.0M-30.3%
Net income-$40.2M-32.3%
EPS (diluted)-$0.16-14.3%

Balance sheet

See full
Cash & equivalents$41.8M+140%
Total debt$31.2M+5.2%
Total equity$143.7M+19.2%
Total assets$192.1M+17.3%

Cash flow

See full
Operating cash flow-$29.7M-13.3%
CapEx$222.0K+1,380%
Free cash flow-$30.0M-14.1%

Valuation

See full
Market cap$1.19B+156%
Enterprise value$1.18B+147%

Profitability

See full
Operating margin-19,183.3%
Net margin-19,305.1%
FCF margin-15,518.7%

Returns & leverage

See full
Return on equity-105.5%+7.0pp
Debt / equity0.2×0.0×
Current ratio10.1×-0.9×

Where this comes from

Reported directly by Savara in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The source filing: Savara’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-344585
Line itemFor the three months ended June 30, 2026For the three months ended June 30, 2025For the six months ended June 30, 2026For the six months ended June 30, 2025
Net loss per share:
Basic and diluted$(0.16)$(0.14)$(0.31)$(0.26)
Weighted-average common shares outstanding:
Basic and diluted253,569,891216,431,348253,426,018216,289,923
Other comprehensive income (loss):
Gain (loss) on foreign currency translation(71)502(166)774
Unrealized loss on short-term investments(34)(86)(281)(240)
Total comprehensive loss$(40,333)$(29,985)$(77,959)$(56,506)

Cover / Front Matter

FAQ

What is Savara's comprehensive income (loss), net of tax, attributable to parent?
Savara (SVRA) reported comprehensive income (loss), net of tax, attributable to parent of -$40.33M in Q2 2026.
How has Savara's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Savara's comprehensive income (loss), net of tax, attributable to parent decreased by 34.5% year-over-year, from -$29.99M to -$40.33M.
What is the long-term trend for Savara's comprehensive income (loss), net of tax, attributable to parent?
Over 4 years (2021 to 2025), Savara's comprehensive income (loss), net of tax, attributable to parent has grown at a 28.1% compound annual growth rate (CAGR), from -$43.95M to -$118.17M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
This metric represents the total change in equity from non-owner sources, encompassing both net income and other comprehensive income items such as foreign currency adjustments and unrealized gains or losses. It provides a more holistic view of the company's financial performance beyond standard operating results. Investors use this to assess the total impact of market and economic factors on the company's overall financial position.

Ask your AI about Savara's comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude